Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
Helena EdlundSun Ku LeeMarilee A AndrewJ Greg SlatterSergey AksenovNidal Al-HunitiPublished in: Clinical pharmacokinetics (2020)
The PK of acalabrutinib and its metabolite ACP-5862 were adequately characterized. Acalabrutinib CL/F decreased with increasing dose, but the trend was small over the 75-250 mg range. No dose adjustment was necessary for intrinsic or extrinsic covariates.
Keyphrases